Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

Oncogene

Volumn 31, Issue 24, 2012, Pages 3002-3008

  Zhang, X ^a,b   Chen, X ^a,b   Lin, J ^a   Lwin, T ^a   Wright, G ^a   Moscinski, L C ^a   Dalton, W S ^a   Seto, E ^a   Wright, K ^a   Sotomayor, E ^a   Tao, J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

lymphoma; miR15a miR 16 1; Myc

Indexed keywords

HISTONE DEACETYLASE 3; LUCIFERASE; MICRORNA 15A; MICRORNA 16; MYC PROTEIN; SMALL INTERFERING RNA; TRICHOSTATIN A; VORINOSTAT;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DLEU2 GENE; EPIGENETICS; GENE; GENE CLUSTER; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACETYLATION; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, NON-HODGKIN; MICRORNAS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

EID: 84862315462     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.470     Document Type: Article

References (29)

1. Aqeilan RI, Calin GA, Croce CM. (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
2. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L et al. (2009). miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559.
3. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R et al. (2010). Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28: 3360-3365.
4. Bhalla KN. (2005). Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993.
5. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
6. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC, degli Uberti EC. (2005). miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 204: 280-285.
7. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529. (Pubitemid 35403967)
8. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
9. Croce CM. (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
10. Davidson-Moncada J, Papavasiliou FN, Tam W. (2010). MicroRNAs of the immune system: roles in inflammation and cancer. Ann NY Acad Sci 1183: 183-194.
11. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. (2001). Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 15: 2069-2082. (Pubitemid 32762051)
12. Garzon R, Marcucci G, Croce CM. (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
13. Haberland M, Montgomery RL, Olson EN. (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
14. Han L, Witmer PD, Casey E, Valle D, Sukumar S. (2007). DNA methylation regulates microRNA expression. Cancer Biol Ther 6: 1284-1288. (Pubitemid 351590384)
15. Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F et al. (2008). Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 26: 4966-4972.
16. Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F et al. (1999). c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 13: 2087-2093.
17. Kurland JF, Tansey WP. (2008). Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 68: 3624-3629.
18. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH et al. (2009). Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 24: 45-50.
19. Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D et al. (2009). DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 315: 2941-2952.
20. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY et al. (2007). Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA 104: 18682-18687. (Pubitemid 350210757)
21. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ et al. (2010). Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29: 5957-5968.
22. Meyer N, Penn LZ. (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
23. Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T et al. (2003). Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120: 434-441. (Pubitemid 36241499)
24. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843. (Pubitemid 40839736)
25. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS et al. (2000). Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. Int J Cancer 87: 787-793. (Pubitemid 30660555)
26. Robertus JL, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y et al. (2010). MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol 149: 896-899.
27. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P et al. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537.
28. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S et al. (2011). Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 30: 2587-2594.
29. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. (2010). microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115: 2630-2639.